Results 1 to 10 of about 648,498 (303)

Prognostic nomograms for predicting cause-specific survival and overall survival of stage I–III colon cancer patients: a large population-based study

Cancer Cell International, 2019
Background The purpose of this study was to build functional nomograms based on significant clinicopathological features to predict cause-specific survival (CSS) and overall survival (OS) in patients with stage I–III colon cancer.
Zheng Zhou, Shaobo Mo, Weixing Dai, Wenqiang Xiang, Lingyu Han, Qingguo Li, Renjie Wang, Lu Liu, Long Zhang, Sanjun Cai, Guoxiang Cai   +10 more
doaj   +1 more source

Prophylactic stoma in robotic radical surgery for low-to-intermediate rectal cancer

Clinical Surgical Oncology
Background: Anastomotic leakage are common and serious complications after surgery for low and intermediate rectal cancers; a prophylactic stoma is thought to reduce the incidence of anastomotic leakage and alleviate its serious complications.
Zhekun Huang, Songbin Lin, Peiwen Zhou, Yang Lv, Guodong He, Ye Wei, Jianmin Xu, Wentao Tang   +7 more
doaj   +1 more source

Clinical Value of Abnormal Prothrombin Combined with CEA, CA72-4 and CA199 on Patients with Gastric Cancer

Zhongliu Fangzhi Yanjiu, 2018
Objective To evaluate the clinical value of abnormal prothrombin (PIVKA-Ⅱ) combined with CEA, CA199 and CA72-4 on the diagnosis, treatment, recurrence and metastasis of patients with gastric cancer. Methods Serum PIVKA-Ⅱ, CEA, CA72-4, CA199 levels in 123
CAI Xiaojuan, WANG Kun, YU Jing
doaj   +1 more source

Risk factors for parastomal hernia of loop stoma and relationships with other stoma complications in laparoscopic surgery era

BMC Surgery, 2020
Background Laparoscopic approach is now a widespread technique used worldwide, but there are few recent studies on risk factors for parastomal hernia. Therefore, this study was performed to analyze the incidence of parastomal hernia in laparoscopic and ...
Takuya Shiraishi, Yuji Nishizawa, Koji Ikeda, Yuichiro Tsukada, Takeshi Sasaki, Masaaki Ito   +5 more
doaj   +1 more source

The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study

BMC Cancer
Background For high-risk stageIImismatch repair deficient (dMMR) colon cancers, the benefit of adjuvant chemotherapy remains debatable. The principal aim of this study was to evaluate the prognostic value of high-risk factors and the effect of ...
Leen Liao, Jinghua Tang, Zhigang Hong, Wu Jiang, Yuan Li, Lingheng Kong, Kai Han, Zhenlin Hou, Chenzhi Zhang, Chi Zhou, Linjie Zhang, Qiaoqi Sui, Binyi Xiao, Weijian Mei, Jiehai Yu, Wanjun Yang, Zhizhong Pan, Pei-Rong Ding   +17 more
doaj   +1 more source

Colorectal Cancer Screening [PDF]

Gastroenterology Research and Practice, 2012
Colorectal cancer (CRC) is the most common malignancy worldwide if men and women are considered together, with more than 1,200,000 new cases per year. The highest incidence rates are found in Australia and New Zealand, Europe, and North America. In addition, it represents, after lung cancer, the second leading cause of cancer-related death among these ...
Quintero, E, Saito, Y, Hassan, Cesare, Senore, C.   +3 more
openaire   +4 more sources

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis

Radiation Oncology, 2017
Background This study aimed to evaluate the efficacy of a high dose of oral tegafur-uracil (400 mg/m2) plus leucovorin with preoperative chemoradiation of locally advanced rectal cancer and to explore the impact of polymorphisms of cytochrome P 2A6 ...
Sun Young Kim, Ji Yeon Baek, Jae Hwan Oh, Sung Chan Park, Dae Kyung Sohn, Min Ju Kim, Hee Jin Chang, Sun-Young Kong, Dae Yong Kim   +8 more
doaj   +1 more source

Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort

BMC Cancer, 2019
Background Patients suffering from high risk stage II colon cancer (CC) may benefit from adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification.
Ann C. Eriksen, Flemming B. Sørensen, Jan Lindebjerg, Henrik Hager, René dePont Christensen, Sanne Kjær-Frifeldt, Torben F. Hansen   +6 more
doaj   +1 more source

UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer

Cell Death and Disease, 2021
UPF1 is proved to dysregulate in multiple tumors and influence carcinogenesis. However, the role of UPF1 in oxaliplatin resistance in colorectal cancer (CRC) remains unknown.
Congcong Zhu, Long Zhang, Senlin Zhao, Weixing Dai, Yun Xu, Yuqin Zhang, Hongtu Zheng, Weiqi Sheng, Ye Xu   +8 more
doaj   +1 more source

Colorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention? [PDF]

The Scientific World Journal, 2012
Colorectal cancer (CRC) is presently one of the most common causes of cancer-related death in our setting and affects a great number of people each year. Screening strategies are commonly used but they do not seem enough to avoid CRC development or prevent completely its mortality.
A. Manzano, P. Pérez-Segura
openaire   +3 more sources